Literature DB >> 22127210

1-Pentyl-3-phenylacetylindoles and JWH-018 share in vivo cannabinoid profiles in mice.

Jenny L Wiley1, Julie A Marusich, Billy R Martin, John W Huffman.   

Abstract

BACKGROUND: Smoking of synthetic cannabinoid-enhanced "herbal incense" is an emerging substance abuse problem. The indole-derived cannabinoids identified in these products were originally developed as research tools and are structurally distinct from cannabinoids in the cannabis plant. Although abused by humans, most published research on this class of compounds has been performed in vitro. The purpose of this study was to evaluate a novel series of 1-pentyl-3-phenylacetylindoles in mice.
METHODS: The potencies of these analogs to produce the cannabinoid agonist effects of antinociception, hypothermia and suppression of locomotion were evaluated in ICR mice. The major structural manipulations in the present series included the type of substituent (i.e., unsubstituted, methyl, methoxy, chloro, bromo, and fluoro) and the position of the substituent on the phenyl ring (i.e., 2-, 3- or 4-position).
RESULTS: Potencies of this series of phenylacetylindoles for each cannabinoid effect were highly correlated with CB(1) receptor affinities reported previously. Active compounds produced a profile of effects that resembled that exhibited by Δ(9)-tetrahydrocannabinol (THC). The most critical factor affecting in vivo potency was the position of the substituent. Whereas compounds with 2- and 3-phenylacetyl substituents were efficacious with good potencies, 4-substituents resulted in compounds that had poor potency or were inactive.
CONCLUSIONS: These results suggest that phenylacetylindoles with good CB(1) binding affinity share pharmacological properties with THC in mice; however, they also emphasize the complexity of molecular interactions of synthetic cannabinoids with CB(1) receptors and suggest that scheduling efforts based solely upon structural features should proceed with caution.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22127210      PMCID: PMC3294131          DOI: 10.1016/j.drugalcdep.2011.11.001

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  34 in total

Review 1.  CB1 cannabinoid receptor ligands.

Authors:  Ganesh A Thakur; Spyros P Nikas; Alexandros Makriyannis
Journal:  Mini Rev Med Chem       Date:  2005-07       Impact factor: 3.862

2.  The role of fluorine substitution in the structure-activity relationships (SAR) of classical cannabinoids.

Authors:  Peter J Crocker; Anu Mahadevan; Jenny L Wiley; Billy R Martin; Raj K Razdan
Journal:  Bioorg Med Chem Lett       Date:  2007-01-13       Impact factor: 2.823

3.  Manipulation of the tetrahydrocannabinol side chain delineates agonists, partial agonists, and antagonists.

Authors:  B R Martin; R Jefferson; R Winckler; J L Wiley; J W Huffman; P J Crocker; B Saha; R K Razdan
Journal:  J Pharmacol Exp Ther       Date:  1999-09       Impact factor: 4.030

4.  Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists.

Authors:  John W Huffman; Gulay Zengin; Ming-Jung Wu; Jianzhong Lu; George Hynd; Kristen Bushell; Alicia L S Thompson; Simon Bushell; Cindy Tartal; Dow P Hurst; Patricia H Reggio; Dana E Selley; Michael P Cassidy; Jenny L Wiley; Billy R Martin
Journal:  Bioorg Med Chem       Date:  2005-01-03       Impact factor: 3.641

5.  Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities.

Authors:  D R Compton; K C Rice; B R De Costa; R K Razdan; L S Melvin; M R Johnson; B R Martin
Journal:  J Pharmacol Exp Ther       Date:  1993-04       Impact factor: 4.030

6.  Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents.

Authors:  D R Compton; M R Johnson; L S Melvin; B R Martin
Journal:  J Pharmacol Exp Ther       Date:  1992-01       Impact factor: 4.030

7.  Pharmacological evaluation of iodo and nitro analogs of delta 8-THC and delta 9-THC.

Authors:  B R Martin; D R Compton; S F Semus; S Lin; G Marciniak; J Grzybowska; A Charalambous; A Makriyannis
Journal:  Pharmacol Biochem Behav       Date:  1993-10       Impact factor: 3.533

8.  Cannabinoid pharmacological properties common to other centrally acting drugs.

Authors:  Jenny L Wiley; Billy R Martin
Journal:  Eur J Pharmacol       Date:  2003-06-27       Impact factor: 4.432

9.  Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics.

Authors:  M A Eissenstat; M R Bell; T E D'Ambra; E J Alexander; S J Daum; J H Ackerman; M D Gruett; V Kumar; K G Estep; E M Olefirowicz
Journal:  J Med Chem       Date:  1995-08-04       Impact factor: 7.446

10.  Withdrawal phenomena and dependence syndrome after the consumption of "spice gold".

Authors:  Ulrich S Zimmermann; Patricia R Winkelmann; Max Pilhatsch; Josef A Nees; Rainer Spanagel; Katja Schulz
Journal:  Dtsch Arztebl Int       Date:  2009-07-03       Impact factor: 5.594

View more
  35 in total

1.  A major glucuronidated metabolite of JWH-018 is a neutral antagonist at CB1 receptors.

Authors:  Kathryn A Seely; Lisa K Brents; Anna Radominska-Pandya; Gregory W Endres; Gregory S Keyes; Jeffery H Moran; Paul L Prather
Journal:  Chem Res Toxicol       Date:  2012-03-15       Impact factor: 3.739

2.  Inhalation exposure to smoke from synthetic "marijuana" produces potent cannabimimetic effects in mice.

Authors:  Jason M Wiebelhaus; Justin L Poklis; Alphonse Poklis; Robert E Vann; Aron H Lichtman; Laura E Wise
Journal:  Drug Alcohol Depend       Date:  2012-07-07       Impact factor: 4.492

Review 3.  Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids.

Authors:  Kathryn A Seely; Jeff Lapoint; Jeffery H Moran; Liana Fattore
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-04-26       Impact factor: 5.067

4.  Cannabinoids in disguise: Δ9-tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles.

Authors:  Jenny L Wiley; Julie A Marusich; Timothy W Lefever; Megan Grabenauer; Katherine N Moore; Brian F Thomas
Journal:  Neuropharmacology       Date:  2013-08-02       Impact factor: 5.250

Review 5.  Baths salts, spice, and related designer drugs: the science behind the headlines.

Authors:  Michael H Baumann; Ernesto Solis; Lucas R Watterson; Julie A Marusich; William E Fantegrossi; Jenny L Wiley
Journal:  J Neurosci       Date:  2014-11-12       Impact factor: 6.167

Review 6.  Synthetic Pot: Not Your Grandfather's Marijuana.

Authors:  Benjamin M Ford; Sherrica Tai; William E Fantegrossi; Paul L Prather
Journal:  Trends Pharmacol Sci       Date:  2017-02-02       Impact factor: 14.819

7.  Cannabinoid-like effects of five novel carboxamide synthetic cannabinoids.

Authors:  Michael B Gatch; Michael J Forster
Journal:  Neurotoxicology       Date:  2018-11-12       Impact factor: 4.294

8.  Behavioral responses to acute and sub-chronic administration of the synthetic cannabinoid JWH-018 in adult mice prenatally exposed to corticosterone.

Authors:  Simone Macrì; Lara Lanuzza; Gustavo Merola; Chiara Ceci; Stefano Gentili; Antonella Valli; Teodora Macchia; Giovanni Laviola
Journal:  Neurotox Res       Date:  2013-01-08       Impact factor: 3.911

9.  Development of a high-performance liquid chromatography-tandem mass spectrometry method for the identification and quantification of CP-47,497, CP-47,497-C8 and JWH-250 in mouse brain.

Authors:  Kimberly L Samano; Justin L Poklis; Aron H Lichtman; Alphonse Poklis
Journal:  J Anal Toxicol       Date:  2014-05-09       Impact factor: 3.367

10.  Novel behavioral assays of spontaneous and precipitated THC withdrawal in mice.

Authors:  Kristen R Trexler; Sara R Nass; Molly S Crowe; Joshua D Gross; Margaret S Jones; Austin W McKitrick; David P Siderovski; Steven G Kinsey
Journal:  Drug Alcohol Depend       Date:  2018-07-07       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.